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Abstract
Background: Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) affects many adult men worldwide. The
currently available therapies offer little or no proven benefit for CP/CPPS. We designed this study to assess the
efficacy of acupuncture therapy for the treatment of CP/CPPS.
Methods: This study is designed as a randomized, sham acupuncture-controlled trial. We will compare patients
with CP/CPPS in an acupuncture group and a sham acupuncture group. Sixty-eight patients will be randomly
allocated to receive acupuncture or sham acupuncture. The treatments will consist of 30-min sessions, three times
weekly, for 8 weeks. The primary outcome measure is change in the weekly mean National Institutes of Health
Chronic Prostatitis Symptom Index (NIH-CPSI) total score from baseline through the 8-week treatment period.
Secondary measures include the NIH-CPSI subscale scores, the total International Prostate Symptom Score (IPSS),
patients’ response rate, and patient satisfaction after treatment. We will also assess changes in the NIH-CPSI total
score from baseline at the 20th and 32nd week of follow-up.
Discussion: This is a randomized, sham-controlled trial of acupuncture treatment for CP/CPPS. The results of this
trial will provide more evidence on whether acupuncture is efficacious for treating CP/CPPS.
Trial registration: Clinical Trials.gov NCT02588274
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Background
Chronic prostatitis/chronic pelvic pain syndrome (CP/
CPPS) is a common prostatic syndrome with a worldwide
prevalence of 2 % to 10 % in adult men [1–3]. Based on a
survey in China, the prevalence of CP/CPPS-like symp-
toms among Chinese men is 4.5 % [4]. CP/CPPS can
present with a wide range of clinical manifestations; the
main symptoms include urogenital pain, lower urinary
tract symptoms, psychological issues and sexual dysfunc-
tion [5]. Compared with other urological conditions, the
aetiologic factors of CP/CPPS are unclear, and its patho-
physiological mechanisms are still poorly understood. It is
hypothesized that inflammation or abnormal activity of
the pelvic nerve and muscle play important roles in this
disease [6]. According to the consensus guidelines, there
is still no standard treatment for CP/CPPS; as a result, in-
dividualized therapy and symptom-based treatment ap-
proaches are recommended [5]. The interventions for CP/
CPPS include medication (alpha-adrenergic antagonists,
antibiotics, pain pharmacotherapies, 5-alpha-reductase in-
hibitors, and phytotherapy), physiotherapy (biofeedback,
acupuncture) and surgical intervention [7–10]. Drugs
such as alpha-adrenergic antagonists and antibiotics have
been considered the initial treatment options for CP/
CPPS, but in most cases, the administration of a single
drug does not relieve multiple symptoms [5]. Hence, other
approaches to prevent and ameliorate CP/CPPS symp-
toms are considered essential. Acupuncture may be a
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currently underestimated option for CP/CPPS treatment.
Based on prior research by Lee et al., acupuncture may re-
lieve the pain-related symptoms of CP/CPPS [11]. Thus
far, although several well-designed randomized controlled
trials (RCTs) related to acupuncture for the treatment of
CP/CPPS have been published [12–15], the recommenda-
tions for CP/CPPS in current guidelines remain at level 5
(the lowest level) [5]. Therefore, we designed this trial to




The aim of this study is to evaluate the efficacy of acu-
puncture in CP/CPPS patients.
Design
This study is a multi-centre, sham-controlled, ran-
domized trial of acupuncture for the treatment of
CP/CPPS that will be conducted in the Guang’anmen
Hospital of China Academy of Chinese Medical Sci-
ences and Yantai Hospital of Traditional Chinese
Medicine from November 2015 to May 2017. All of
the patients will be asked to sign an informed con-
sent form prior to randomization. Blinded evaluators
and statisticians will manage all data. We developed
this protocol according to the Standard Protocol
Items: Recommendations for Interventional Trials
(SPIRIT) checklist [16]. This trial protocol has been
approved by the Research Ethical Committee of
Guang’anmen Hospital of China Academy of Chinese
Medical Sciences and Yantai Hospital of Traditional
Chinese Medicine, and it has been registered under
the identifier NCT02588274 at ClinicalTrials.gov in
the USA. Figure 1 provides a study flow chart.
Participants
Sixty-eight patients will be recruited from the Guang’an-
men Hospital of Chinese Academy of Chinese Medical
Sciences and Yantai Hospital of Traditional Chinese
Medicine.
Inclusion criteria
Patients must meet the diagnostic criteria from the NIH
CP/CPPS consensus [17], including the following:
1. History of pain perceived in the prostate region and
absence of other lower urinary tract pathology for a
minimum of three of the past 6 months. In addition,
any associated lower urinary tract symptoms, sexual
function, and psychological factors should be
addressed. Physical examinations, urine analyses,
and urine cultures will be performed for all subjects.
2. Age 18 to 50 years
3. NIH Chronic Prostatitis Symptom Index (NIH-
CPSI) total score ≥ 15 (scale 0–43, with 0 meaning
no symptoms).
Exclusion criteria
1. Other urologic diseases, such as acute prostatitis,
bacterial prostatitis, benign prostatic hyperplasia
(BPH), prostate cancer, urinary tuberculosis, and
urinary tract infection. (The 2-glass test will be per-
formed in patients with urinary tract symptoms
using their voided bladder 2 (VB2) and VB3, which
can provide fairly accurate results and is easy to per-
form [18].)
2. Serious or acute diseases involving the heart, liver,
kidney or blood.
3. Patients receiving acupuncture or medication
(including alpha blockers or pain killers) in the week
prior to the baseline assessment.
Recruitment procedures
We will recruit the participants using advertisements in
newspapers, on television, and on the Internet. Prospect-
ive participants will obtain a good understanding of the
trial by reading the advertisement, which will include a
brief introduction of the population needed, the contact
information of the researchers, and details of the acu-
puncture intervention and of the comparison (all partici-
pants will be informed that there are two acupuncture
groups, i.e., a traditional acupuncture group and a sham
acupuncture group, in which blunt needles are used to
stimulate the acupoint skin, and that they have a 50 %
chance of being allocated into either of the two groups).
If the patient is eligible and interested in the trial, they
will be invited to consult with the study doctors; after
the doctors have provided a diagnosis, the patients will
be recruited. All of the participants will be required to
sign an informed consent form before the trial that will
include an introduction of CP/CPPS, the inclusion and
exclusion criteria of the trial, and an introduction to the
interventions. In addition, participants have the right to
withdraw from the trial at any time.
Randomization
After the participants have completed a baseline evalu-
ation and met the selection criteria, one research assist-
ant, uninvolved with the treatment and data collection,
will be responsible for randomly grouping the partici-
pants. The acupuncturists will be blinded to the process
of randomized assignment. The random sequence will
be generated by the Institute of Clinical Pharmacology
affiliated to Guang’anmen Hospital of China Academy of
Chinese Medical Sciences. Randomization numbers
using a block of four will be sealed in a scheduled
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computer-generated opaque randomization envelope. To
ensure that randomization is successfully implemented,
the patient’s sequence number will be written outside of
the envelope, and a paper-written group name will be in-
side the envelope. All envelopes will be numbered se-
quentially. The envelopes will be delivered according to
the patients’ screening sequence numbers. Finally, the
acupuncturist will be informed of the random numbers
and the group assignment by telephone or e-mail.
Interventions and comparison
Treatment group
According to records in the ancient Traditional Chinese
Medicine work Huangdi Neijing, acupuncture points be-
longing to bladder meridian (BL) have a noticeable effect
on urinary disease. Furthermore, spleen meridian (SP),
kidney meridian (KI), and liver meridian (LR) intersect
at Sanyinjiao (SP 6), one of the most frequently used
acupuncture points for urogenital disease [19, 20]. In
addition, the treatment was based on the theory of
neuroanatomy [10, 21, 22] and consensus among acu-
puncture experts in Guang’anmen Hospital. Therefore,
we chose the following acupuncture points: Zhongliao
(BL 33), Shenshu (BL 23), Huiyang (BL 35), and Sanyin-
jiao (SP 6) (Table 1). After the patients are relaxed and
in a prone position, acupuncturists will use 75 % alcohol
pads to sterilize the skin around the acupuncture points
and then insert steel needles (Huatuo, Suzhou, China
0.3 mm*40 mm/0.3 mm*75 mm) into the acupuncture
points. For bilateral Zhongliao (BL 33), the needle will
be inserted approximately 50–60 mm with a 45-degree
angle. For Huiyang (BL 35), the needle will be inserted
approximately 50–60 mm. For Shenshu (BL 23) and
Sanyinjiao (SP 6), the needles will be inserted vertically
to a depth of 25–30 mm. Acupuncturists will twirl at
BL23, BL35 and SP 6 to achieve and enhance the sensa-
tion of aches, heaviness or numbness in the area sur-
rounding the inserted needle (known as de qi), and the
manipulations will be performed a total of three times
during 1 session (every 10 min). For bilateral BL 33,
which are located in the 3rd posterior sacral foramina,
needles will be inserted without lifting or rotating based
on the characteristics of the points. There are 24 treat-
ment sessions after baseline that occur three times a
week, and the participants will receive a 30-min treat-
ment each session.
Control group
The control group will receive sham acupuncture at the
same acupuncture points as the treatment group. The
sham needle with a blunt tip used in the control group
is similar to the Streitberger needle (Fig. 2 provides a
diagram to illustrate the sham acupuncture applied in
this trial) [23]. Acupuncturists will gently lift, thrust, and
twist the sham needles to simulate the treatment pro-
cedure, thus blinding the patients to the intervention.
Each acupuncture point will undergo the same twirling
motion as the acupuncture group. The duration and
Fig. 1 Flow chart
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frequency of the sessions will be the same as in the acu-
puncture group. To ensure blinding, the investigators will
make appointments with each participant on alternate
days to prevent crosstalk between groups. To test the suc-
cess of the blinding, the participants will be asked to an-
swer the following question after the 4th week treatment:
“Do you think you received traditional acupuncture (A) or
sham acupuncture (blunt needles used to stimulate the
acupoint skin) (B)?” The participants can answer “A”, “B”
or “unclear” (these two interventions will be demonstrated
before the treatment, and all participants will have a good
understanding of both interventions). Any medication
usage should be recorded, including the name of the
medicine, the dosage and the session. We will compare
the proportion of subjects using medicine and the mean
days of medication use between the groups.
Outcome measures
Primary outcome measures
The primary outcome of this study is the change in the
NIH-CPSI total score, which will be measured from
baseline to the 8th week. After we have collected data for
8 weeks, the average score from each week will be
calculated.
The NIH-CPSI is a validated, self-reported ques-
tionnaire that is widely used to assess CP/CPPS pa-
tients [24, 25]. It contains 13 items that are scored
in three discrete domains: pain, urinary symptoms
and impact on quality of life. A score of 0 indicates
that the condition described in the question never
occurs.
The secondary outcome measures include the follow-
ing (for the first three secondary outcomes, we will
measure the change from baseline):
1. NIH-CPSI total score at the 20th and 32nd week.
2. NIH-CPSI subscale scores at the 4th, 8th, 20th, and
32nd week.
3. IPSS total score at the 4th, 8th, 20th, and 32nd week.
The International Prostate Symptom Score (IPSS) is
another valid, reliable and sensitive measure for
patients with lower urinary tract symptoms (LUTS).
The IPSS has been translated into several languages,
including Chinese, and it is widely used in clinical
practice and research to determine the severity of
LUTS, including incomplete bladder emptying,
frequency of urination, intermittency, urgency, weak
urine stream, straining and nocturia [26, 27]. Each
of the questions is rated from 0 (not at all) to 5
(almost always), and according to the total symptom
score, the severity of LUTS can be graded as mild
(0–7), moderate (8–19) or severe (20–35).
4. Global response assessment at the 4th, 8th, 20th, and
32nd week. Patients who have at least a 50 %
decrease compared to baseline in total NIH-CPSI
score will be considered “responders”. We will com-
pare the response rate between the two groups.
5. Expectations that acupuncture might help CP/CPPS
at baseline. This scale includes four brief questions
to investigate whether patients are confident that
acupuncture treatment will help their CP/CPPS.
6. The degree of satisfaction for patients undergoing
acupuncture treatment will be measured at the 8th,
20th, and 32nd week.
Table 1 Measurements at different time points
Measurements baseline 1 week 2 weeks 3 weeks 4 weeks 5 weeks 6 weeks 7 weeks 8 weeks 20 weeks 32 weeks
NIH-CPSI total score × × × × × × × × × × ×
NIH-CPSI subscales score × × × × ×
IPSS total score × × × × ×
Global response assessment × × × × ×
Degree of expectation ×
Satisfation × × ×
NIH-CPSI The National Institutes of Health Chronic Prostatitis Symptom Index, IPSS International Prostate Symptom Score
Fig. 2 Sham acupuncture used in this trial
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Table 1 shows the time to visit and the data collection
measurements at different time points.
Safety assessment
Adverse events (AEs) related to acupuncture treatment
will be appropriately assessed and recorded by the ob-
servers throughout the trial, for instance, pain, haemato-
mas, or nausea. AEs will be managed by acupuncturists
and related clinical specialists within 24 h. The principal
investigator (Z. Liu) will make the final decision to ter-
minate the trial if severe AEs arise.
Data collection and quality control
Because nonstandard input of clinical data can contrib-
ute to the bias of results, two investigators (to assess the
effect of treatment) will independently collect the data
using case report forms and then input the data into a
computer; this process will ensure the safety and reliabil-
ity of the data. To confirm the quality of the trial, all
acupuncturists will be required to have an official license
and more than two years of clinical experience.
Sample size calculation and statistical analysis
The calculation of sample size was based on the primary
outcome of change in NIH-CPSI total score from base-
line to the 8th week of treatment (mean of 8 weeks of
data). According to previous literature [12], after
10 weeks of sham acupuncture treatment, NIH-CPSI
scores decreased by 6.2, with a standard deviation of
10.3. We estimated that for a 13.3-point difference in
the NIH-CPSI score with a standard deviation of 4.5,
and based on our clinical experience and data from pre-
vious research, the decrease in the NIH-CPSI total score
should be more than 6 points (i.e., the minimal clinically
important difference, MCID) [28]. Therefore, we will
need to recruit 34 patients per group from Guang’anmen
Hospital of Chinese Academy of Chinese Medical Sci-
ences and Yantai Hospital of Traditional Chinese Medi-
cine to obtain 90 % power and a significance level of 5 %
while allowing for a 20 % dropout rate.
The data will be analysed using SPSS software Ver.19.0
(IBM SPSS Statistics, IBM Corp, Somers, New York),
and the data analysis will be based on the intention-to-
treat (ITT) principle regarding baseline characteristics. If
there are significantly more dropouts in the control
group than in the treatment group, we will conduct a
secondary analysis of subjects who have completed the
treatment according to the protocol. The outcomes for
evaluating changes between the groups will be based on
the outcome of the NIH-CPSI at different time points.
The significance levels will be two-sided and reported at
a 5 % level. For continuous measurement data, the
mean, standard deviation, median and interquartile
range will be represented. If the data are normally
distributed, analysis of covariance will be used because
the centres and baseline variables in this study are covar-
iates that are not manipulated by the researchers but
may still have an effect on the efficacy of acupuncture. If
the distribution is not normal, we will use generalized
estimating equations, if needed, to account for the cu-
mulative acupuncture frequency and to observe whether
increasing treatment sessions results in increased effi-
cacy for patients. Linear regression will be used to ex-
plore whether the patients’ expectations have an impact
on treatment. For categorical data, a CMH (Cochran-
Mantel-Haenszel) test will be used, and the data will be
represented as case and percentages. Missing data will
be assumed to be missing randomly and will be imputed
using multiple imputation.
Table 2 summarizes the details of the analysis methods
for the primary and secondary outcomes.
Discussion
Acupuncture has been used to treat urinary diseases in
China for centuries, and many RCTs have been focused
on this illness [29–33]. Several RCTs to date have shown
that acupuncture or electro-acupuncture is effective for
CP/CPPS [12–14]; however, according to a systematic
review and the consensus guidelines, positive evidence
for acupuncture-based therapy in CP/CPPS remains
poor [17, 34]. The lack of evidence is mainly attributable
to the methodological limitations of prior studies, such
as inappropriate trial designs, inadequate control groups,
lack of follow-up, and lack of suitable outcome mea-
sures. Some well-designed trials have indicated that the
effect of invasive sham acupuncture may be comparable
to that of real acupuncture or standard drug therapy [35,
36]. These results might call into question whether the
“invasive sham acupuncture” is a reasonable control for
CP/CPPS or whether it is actually a type of shallow acu-
puncture intervention. Several researchers have also ar-
gued about whether invasive sham procedures can be
incorporated by acupuncture trials [37, 38]. We are also
curious about this question, and we designed the sham
acupuncture to use a blunt-tip needle on acupoints with-
out penetration. According to the findings of our prior
crossover study, this non-insertion-type needle is a valid
sham control for acupuncture research and can achieve
good subject blinding effects with a similar appearance
to traditional acupuncture [39]. Given a sufficiently thin
needle and the manipulation used (lifting, thrusting or
rotating), even blunt tips can make participants feel the
sensation of piercing. Most of the participants were
hardly able to distinguish this device from real acupunc-
ture in the previous trial [39]. In addition, in the current
trial, we will use BL 23, BL 33, BL 35 and SP 6 as the se-
lected acupoints instead of conception vessel 1 (CV 1)
and CV 4. According to our previous clinical
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experiences and studies related to BPH, acupuncture on
BL 23, BL 33, and BL 35 could significantly improve the
condition of patients with LUTS [40]. Furthermore, the
selected acupoints mentioned above are located on the
participant’s lower back and distal lower extremity;
therefore, the participants will barely be able to see the
treatment procedure and puncture wounds from their
prone position. Thus, we anticipate that the acupoints
chosen in this trial might increase the possibility of
patient-blinding.
In this trial, we aim to clarify the efficacy and safety of
acupuncture for treating CP/CPPS. We will calculate the
mean NIH-CPSI scores over 8 weeks, and these scores
will indicate the weekly efficacy of acupuncture during
the 8 weeks of treatment; additionally, the mean value
may provide more sufficient evidence for determining
whether acupuncture is efficacious for treating CPPS.
Furthermore, we will add an expectations scale to ex-
plore whether the patients’ expectations have a potential
impact on the outcomes of acupuncture treatment.
Nevertheless, this study has several limitations, including
the small sample size and the unblinded acupuncturists.
Due to the use of a sham acupuncture control, a rela-
tively high rate of dropouts might be observed in the
control group. Additionally, there is a risk that the blind-
ing method may be unsuccessful in control participants,
as the blunt tip needle will not leave puncture holes.
Finally, a few participants might be recruited mistakenly
due to the overlapping symptoms of CP/CPPS and BPH
[41]. Nonetheless, the outcome assessors and patients
will be blinded to decrease the potential for bias [42].
We hope that the results of this trial can provide both
an evidence-based treatment option for patients suffer-
ing from CP/CPPS and an enhanced level of evidence on
which to base guideline recommendations.
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